Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
July 09, 2024 08:00 ET
|
Caribou Biosciences, Inc.
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences,...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2024 19:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 16:05 ET
|
Caribou Biosciences, Inc.
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...
Caribou Biosciences to Participate in Upcoming Investor Conferences
May 01, 2024 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
April 04, 2024 16:00 ET
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024 16:05 ET
|
Caribou Biosciences, Inc.
-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for...
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024 16:30 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 15, 2024 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Gene Switch/Molecular Switch Market projected to reach USD 1.4 Billion by 2030, growing at a CAGR of 11.3% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study
February 15, 2024 08:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 15, 2024 (GLOBE NEWSWIRE) -- According to a research report "Gene Switch/Molecular Switch Market”, by Product Type (CAR-T Cell Therapies, Gene Therapies, Others), Payment model...
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
January 07, 2024 11:00 ET
|
Caribou Biosciences, Inc.
-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...